Loading stock data…
GKOS
$126.34+4.38 (+3.59%)
After Hours$126.34+0.00 (+0.00%)· Last close Jun 9
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Glaukos Corporation in the Healthcare sector is trading at $126.34 with a market capitalization of $6.7B. Wall Street consensus targets $154.50 (12 analysts), implying a +22.3% move over the next 12 months. The stock is currently 15% below its 52-week high of $148.11, remaining 18.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$126.34
Potential Downside
0%
Whystock Fair Value$126.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$154.50+22.3%
Range$136.00 – $170.00
Fundamentals
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.22%
Volume
Today's trading volume
929,244
Recent News
A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings
Glaukos share performance snapshot after recent moves Glaukos (GKOS) has drawn fresh attention after recent trading swings, with the stock up about 18% over the past week but down nearly 9% over the past month. That short term volatility sits against a longer record where the stock shows gains over the past 3 months, year to date and past year, leaving investors weighing how current pricing aligns with the company’s ophthalmic therapy pipeline and financial profile. See our latest analysis...
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
Glaukos, a medical technology company focusing on eye disorders, has achieved gains of 20% year to date and 48% over the last year.
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations
Glaukos now sits on an updated fair value estimate of about US$151.08 per share, up from US$138.75, reflecting refreshed analyst models around the name. That shift lines up with recent Street commentary, where higher price targets generally echo confidence in the product ramp story while still calling out execution risk and long term expectations. As you read on, you will see how these moving targets shape the evolving Glaukos narrative and what to watch next in the data and...
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out
Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.